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Abstract Aims/hypothesis: Circulating levels of adipo-
nectin are negatively associated with multiple indices of
insulin resistance, and the concentration is reduced in
humans with insulin resistance and type 2 diabetes.
However, the mechanisms by which adiponectin improves
insulin sensitivity remain unclear. Subjects and methods:
Combining euglycaemic–hyperinsulinaemic clamp studies
with indirect calorimetry and skeletal muscle biopsies, we
examined the relationship between plasma adiponectin and
parameters of whole-body glucose and lipid metabolism,
and muscle glycogen synthase (GS) activity in 51
Caucasians (ten lean, 21 obese and 20 with type 2
diabetes). Results: Plasma adiponectin was significantly
reduced in type 2 diabetic compared with obese and lean
subjects. In lean and obese subjects, insulin significantly
reduced plasma adiponectin, but this response was blunted
in patients with type 2 diabetes. Plasma adiponectin was
positively associated with insulin-stimulated glucose
disposal (r=0.48), glucose oxidation (r=0.54), respiratory
quotient (r=0.58) and non-oxidative glucose metabolism
(r=0.38), and negatively associated with lipid oxidation
during insulin stimulation (r=−0.60) after adjustment for
body fat (all p<0.01). Most notably, we found a positive
association between plasma adiponectin and insulin stim-
ulation of GS activity in skeletal muscle (r=0.44, p<0.01).
Conclusions/interpretation: Our results indicate that plas-
ma adiponectin may enhance insulin sensitivity by
improving the capacity to switch from lipid to glucose
oxidation and to store glucose as glycogen in response to
insulin, and that low adiponectin may contribute to
impaired insulin activation of GS in skeletal muscle of
patients with type 2 diabetes.
Keywords Adiponectin . AMP-activated protein kinase .
Glycogen synthase . Insulin resistance . Non-oxidative
glucose metabolism . Type 2 diabetes mellitus
Abbreviations ACC: acetyl CoA carboxylase .
AMPK: AMP-activated protein kinase . FV: fractional
velocity . GS: glycogen synthase . IR: insulin receptor .
NOGM: non-oxidative glucose metabolism .
Rd: glucose disposal rates . TR-IFMA: time-resolved
immunofluorometric assay
Introduction
Adiponectin is a novel adipocyte-specific protein, which is
present abundantly in the circulation in humans [1]. In
contrast to other adipokines, such as leptin, TNF-α and
resistin, adiponectin levels are decreased in obesity [1–3],
and show a strong negative correlation with multiple
indices of insulin resistance in humans in vivo [2–8]. In
patients with type 2 diabetes, adiponectin levels are further
reduced [2, 3], and low plasma adiponectin predicts a
decline in insulin sensitivity and the future development of
type 2 diabetes [9, 10]. Furthermore, treatment of type 2
diabetes with thiazolidinediones seems to involve in-
creased secretion of adiponectin from adipose tissue in
response to activation of peroxisome proliferator-activated
receptor-γ [3, 8, 11]. While further studies are needed to
establish the pathophysiological role of reduced plasma
adiponectin in type 2 diabetes, these data support the
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hypothesis that adiponectin may be a key regulator of
insulin sensitivity and energy metabolism [1].
The physiological and molecular mechanisms under-
lying the insulin-sensitising effect of adiponectin in vivo
remain to be fully clarified, but studies in rodents and cell
cultures indicate that adiponectin stimulates fatty acid
oxidation and glucose uptake in muscle [12–15], and
augments insulin-mediated suppression of hepatic glucose
output [16, 17]. These effects may be mediated by the
binding of adiponectin to one of two recently identified
adiponectin receptors, termed AdipoR1 and AdipoR2 [18],
and subsequent activation of AMP-activated protein kinase
(AMPK) and downstream signalling molecules [12, 13,
19]. Chronic pharmacological activation of AMPK in
rodents improves not only fatty acid oxidation and glucose
uptake but also mitochondrial biogenesis in muscle [20,
21]. Furthermore, novel approaches such as magnetic
resonance spectroscopy, gene expression profiling and
proteome analysis of human skeletal muscle support a role
for impaired mitochondrial oxidative phosphorylation and
ATP synthesis in type 2 diabetes [22–25]. For these
reasons, the hypothesis of blunted signalling along the
adiponectin-AMPK signalling pathway in insulin resis-
tance is attractive [1]. However, we and others have found
normal AMPK activity and isoform protein expression in
muscle biopsies from obese non-diabetic and type 2
diabetic subjects [26–28], which indicates that adiponectin
may enhance insulin sensitivity by regulating signalling
through alternative pathways. Correspondingly, adiponec-
tin has been reported to augment insulin-mediated tyrosine
phosphorylaton of the insulin receptor (IR) and IRS-1 in
rodent skeletal muscle [14]. In addition, a cross-sectional
study of lean, obese and type 2 diabetic individuals showed
that low adiponectin levels were associated with a lower
fold-increase in tyrosine phosphorylation of muscle IR in
response to insulin [5]. Thus, there is evidence that low
plasma adiponectin might interfere with insulin signalling,
leading to impaired glucose transport and glycogen
synthesis. Skeletal muscle is the major site of insulin
resistance, and quantitatively impaired muscle glycogen
synthesis is the major defect of insulin-stimulated glucose
metabolism in type 2 diabetes [29]. Correspondingly,
impaired insulin activation of muscle glycogen synthase
(GS) is a consistent finding in patients with type 2 diabetes
and high-risk individuals [29, 30]. Recently, an association
between plasma adiponectin and insulin-stimulated non-
oxidative glucose disposal was demonstrated in offspring
of patients with type 2 diabetes [6]. Based on these findings
we hypothesised that low adiponectin levels may con-
tribute to impaired insulin activation of muscle GS in
patients with type 2 diabetes.
To investigate possible mechanisms underlying the
insulin-sensitising effect of adiponectin in humans in
vivo, we examined the association of plasma adiponectin
with measures of whole-body lipid and glucose metabo-
lism and muscle GS activity in a cross-sectional population
of lean, obese and type 2 diabetic subjects. Our investiga-
tions combined euglycaemic–hyperinsulinaemic clamp




A total of 51 Caucasians participated in the study. This
included ten healthy lean, 21 healthy obese and 20 obese
type 2 diabetic subjects, who were consecutively enrolled
for euglycaemic–hyperinsulinaemic clamp studies com-
bined with skeletal muscle biopsies (Table 1). We have
previously reported α1- and α2-AMPK activity, phosphor-
ylation of AMPK on Thr172, and phosphorylation of acetyl
CoA carboxylase (ACC) on Ser221 in skeletal muscle
biopsies obtained from the first 20 participants enrolled in
the present study (ten obese type 2 diabetic and ten obese
control subjects, all males) [26]. Type 2 diabetic patients
were treated by diet either alone or in combination with
sulfonylurea, metformin or insulin, which were withdrawn
1 week prior to the study. The patients were all GAD65
antibody negative and without signs of diabetic retinopa-
thy, nephropathy, neuropathy or macrovascular complica-
Table 1 Clinical and biochem-
ical characteristics (means±
SEM)
ap<0.01 vs lean subjects,
bp<0.01 and cp<0.05 vs obese
control subjects
Subjects
Lean control Obese control Diabetic
Male/female 5/5 16/5 16/4
Age (years) 50.8±1.0 49.8±1.2 50.2±1.1
BMI (kg/m2) 24.2±0.5 31.8±1.0a 32.3±0.8a
Percent body fat 25.9±2.3 35.8±1.8a 35.9±1.5a
Plasma glucose (mmol/l) 5.7±0.1 5.7±0.1 10.4±0.7a,b
Serum insulin (pmol/l) 24.3±5.7 50.6±4.1a 84.4±7.0a,b
Serum C-peptide (pmol/l) 456±48 765±50a 1,114±65a,b
HbA1c (%) 5.5±0.1 5.2±0.1 7.3±0.4
a,b
Total cholesterol (mmol/l) 5.3±0.2 5.5±0.2 5.6±0.2
LDL cholesterol (mmol/l) 2.9±0.2 3.5±0.2 3.3±0.2
HDL cholesterol (mmol/l) 1.8±0.1 1.4±0.1a 1.2±0.1a
Plasma triglycerides (mmol/l) 1.1±0.2 1.4±0.1 2.7±0.5a,c
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tions. All the control subjects had normal glucose tolerance
and no family history of diabetes. However, on the clamp
day, one lean and three obese control subjects showed
fasting plasma glucose levels consistent with IFG. All
subjects had normal results on screening blood tests of
hepatic and renal function. All subjects were instructed to
refrain from strenuous physical activity for a period of 48 h
before the experiment. Informed consent was obtained
from all subjects before participation. The study was
approved by the Local Ethics Committee and was
performed in accordance with the Helsinki Declaration.
Study design
All study subjects were admitted to the Diabetes Research
Centre at Odense University Hospital, Denmark. After an
overnight fast the subjects underwent a euglycaemic–
hyperinsulinaemic clamp. After a 2-h basal tracer equilibra-
tion period, insulin was infused at a rate of 40 mU·m−2·min−1
for 4 h. A primed-constant [3-3H]glucose infusion was
used throughout the 6-h study, and [3-3H]glucose was
added to the glucose infusates to maintain plasma specific
activity constant at baseline levels during the 4-h clamp
period as described in detail previously [31]. Using this
protocol, physiological hyperinsulinaemia at a serum
insulin concentration of ∼400 pmol/l was obtained in all
groups during the insulin-stimulated period. In type 2
diabetic subjects, plasma glucose was allowed to decline to
∼5.5 mmol/l during the initial part of the 4-h insulin
infusion period before glucose infusion was initiated. Total
glucose disposal rates (Rd) were calculated using Steele’s
non-steady-state equations adapted for labelled glucose
infusates as described [31]. The distribution volume of
glucose was taken as 200 ml/kg body weight and the pool
fraction as 0.65. The studies were combined with indirect
calorimetry using a flow-through canopy gas analyser
system (Deltatrac; Datex, Helsinki, Finland). After an
equilibration period of 10 min, the average gas exchange
recorded over the two 30-min steady-state periods (basal
and insulin-stimulated) were used to calculate the RQ and
rates of glucose and lipid oxidation as previously described
[32]. Rates of non-oxidative glucose metabolism (NOGM)
were calculated as the difference between Rd and glucose
oxidation. Percent body fat was determined by the
bioimpedance method.
Assays
Plasma adiponectin was determined by an in-house time-
resolved immunofluorometric assay (TR-IFMA) based on
commercial antibodies and recombinant human adiponec-
tin (R&D Systems, Abingdon, UK) as recently described
[33]. Adiponectin has a molecular mass of ∼30–36 kDa
depending on the degree of glycosylation, but the molecule
is known to form a wide range of polymers in vivo. The
predominant polymers include trimers, hexamers and
highly congregated multimers of ∼300 kDa. Both anti-
bodies of the present assay were able to detect several
adiponectin polymers in serum, including the three major
molecular forms (data not shown). Within- and between-
assay CV values of standards and unknown samples
averaged <5 and 10%, respectively. Plasma glucose was
measured at the bedside on a Beckman glucose analyser
(Beckman Instruments, Fullerton, CA, USA) by the
glucose oxidase method. Serum insulin and C-peptide
were analysed by commercial TR-IFMAs (Perkin Elmer
Life Sciences, Turku, Finland), and serum NEFA and
triglycerides were measured by an enzymatic colorimetric
method (Wako Chemicals, Neuss, Germany).
Muscle biopsies
Muscle biopsies were obtained from the vastus lateralis
muscle before and after the 4-h insulin infusion period
using a modified Bergström needle with suction under local
anaesthesia (10–15 ml lidocaine 2% [20 g/l] injected s.c.).
Muscle samples were immediately blotted free of blood, fat
and connective tissue and frozen in liquid nitrogen within
20–30 s. The muscle samples were freeze-dried and
dissected free of blood, fat and connective tissue before
analysis of muscle enzyme activity, which was measured in
muscle homogenates as described previously [30].
GS activity
GS activity was measured in homogenates by a method
described by Richter et al [34]. GS activity was determined
in the presence of 0.17 or 8 mmol/l glucose-6-phosphate
and given as the percent of fractional velocity (FV)
(100×activity in the presence of 0.17 mmol/l glucose-6-
phosphate divided by the activity at 8 mmol/l glucose-6-
phosphate).
Statistical analysis
Data calculation and statistical analysis were performed
using the SPSS for Windows Version 10.0 program.
Variables with skewed distribution (insulin and adiponec-
tin) were logarithmically transformed for statistical anal-
ysis. Results are given as means±SEM. Differences
between the groups were assessed with one-way ANOVA
and Tukey’s post hoc testing. Differences within groups
were evaluated using Student’s t-test for paired data. The
relationships between plasma adiponectin and continuous
variables were examined by calculation of Pearson’s
correlation coefficients, and partial correlation was used
to examine relationships between plasma adiponectin and
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continuous variables, independently of percent body fat.
Significance was accepted at the p≤0.05 level.
Results
Characteristics
Anthropometric and biochemical characteristics of the
study subjects are shown in Table 1. The lean subjects had
significantly lower BMI and percent body fat, and
significantly higher plasma HDL cholesterol than obese
subjects and type 2 diabetic patients. Fasting levels of
plasma glucose, plasma triglycerides, HbA1c, serum insulin
and C-peptide were significantly higher in type 2 diabetic
patients than in lean and obese subjects. Serum insulin and
C-peptide levels were also significantly higher in obese
than in lean subjects (Table 1).
Metabolic studies
Metabolic characteristics of the study subjects are shown in
Table 2. Basal Rd were significantly higher in type 2
diabetic patients than in obese subjects, whereas basal
serum NEFA and basal rates of glucose oxidation, NOGM,
RQ and lipid oxidation were similar in the three groups. In
the insulin-stimulated state, Rd, glucose oxidation, NOGM
and RQ were significantly reduced, and lipid oxidation and
serum NEFAwere significantly increased in type 2 diabetic
patients compared with obese and lean subjects. Except for
NOGM and serum NEFA the same differences were seen
between obese and lean subjects.
Plasma adiponectin
Basal plasma adiponectin levels were significantly lower in
patients with type 2 diabetes (5.7±0.5 mg/l) than in obese
(8.7±1.1 mg/l; p=0.05) and lean (10.6±1.6 mg/l; p=0.008)
subjects (Fig. 1a). There was no difference between lean
and obese subjects (p=0.45). The administration of insulin
in physiological concentrations over 4 h caused a small but
significant reduction in plasma adiponectin levels in lean
(7.9%; p<0.001) and obese (5.1%; p<0.001) subjects. In
patients with type 2 diabetes, the insulin-mediated sup-
pression of plasma adiponectin was not significant (2.2%;
p=0.08). The insulin-mediated decrease in plasma adipo-
nectin was significantly impaired in type 2 diabetic subjects
compared with lean subjects, but not when compared with
obese subjects (Fig. 1b).
GS activity
In the basal state there was no difference between the three
groups in GS FV activity (Fig. 1c). Insulin infusion
significantly increased GS FV activity in lean and obese
subjects (both p<0.001), but not in patients with type 2
diabetes (p=0.16). In the insulin-stimulated state GS FV
activity was significantly lower in type 2 diabetic and obese
subjects compared with lean subjects (Fig. 1c). Further-
more, insulin-stimulated GS FV activity was significantly
lower in patients with type 2 diabetes compared with obese
subjects (Fig. 1c). The increase in GS FV activity (Δ-GS
FV) induced by insulin was significantly lower in patients
with type 2 diabetes compared with obese and lean
subjects, and also in obese compared with lean subjects
(Fig. 1d).
Adiponectinaemia in relation to metabolic parameters
To explore possible mechanisms underlying the insulin-
sensitising effect of circulating adiponectin in humans in
vivo, we examined the relationship between basal plasma
adiponectin and insulin action on whole-body parameters
of lipid and glucose metabolism after adjustment for
percent body fat. Basal plasma adiponectin was positively
associated with insulin-stimulated values of Rd, glucose
oxidation, NOGM and RQ, and negatively associated with




Metabolic rates are expressed as
milligrams per square metre per
minute (mg·m−2·min−1)
ap<0.01 vs lean subjects,
bp<0.01 vs obese control
subjects
Subjects
Lean control Obese control Diabetic
Rd basal 81±5 77±2 90±3
b
Rd clamp 352±18 266±17
a 159±16a,b
Glucose oxidation basal 51±7 49±4 47±5
Glucose oxidation clamp 137±10 104±4a 72±5a,b
NOGM basal 30±7 28±4 40±4
NOGM clamp 215±16 166±14 91±4a,b
Lipid oxidation basal 44±3 46±2 52±3
Lipid oxidation clamp 11±3 23±2a 39±2a,b
RQ basal 0.80±0.01 0.80±0.01 0.79±0.01
RQ clamp 0.96±0.02 0.90±0.0a 0.83±0.01a,b
Serum NEFA (mmol/l) basal 0.54±0.07 0.52±0.05 0.50±0.03
Serum NEFA (mmol/l) clamp 0.03±0.00 0.05±0.01 0.09±0.01a,b
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(Fig. 2a–d). In the subgroup of male subjects (n=38) these
relationships remained significant (Fig. 2a–d).
To study the potential role of insulin-mediated suppres-
sion of plasma adiponectin with respect to insulin sensi-
tivity, we also examined the relationship between the
relative decrease in plasma adiponectin (clamp adiponectin
divided by basal adiponectin) and these parameters of
insulin action after adjustment for percent body fat. The
relative decrease in plasma adiponectin correlated posi-
tively with insulin-stimulated values of Rd (r=0.32;
p=0.02), glucose oxidation (r=0.40; p=0.005) and RQ
(r=0.39; p=0.008), and negatively with lipid oxidation (r=
−0.38; p=0.008) during insulin stimulation, whereas no
significant relationship with NOGM (r=0.22; p=0.14) or
serum NEFA (r=−0.24; p=0.09) was observed.
Adiponectinaemia in relation to GS and AMPK
activity
To gain insight into potential molecular mechanisms by
which plasma adiponectin increases skeletal muscle insulin
sensitivity, we examined the relationship between plasma
adiponectin and muscle GS activity (Table 3). There was
no association between plasma adiponectin and GS FV
activity in the basal state. In contrast, basal plasma
adiponectin was positively associated with GS FV activity
in the insulin-stimulated state as well as with Δ-GS FV
activity both before (not shown) and after adjusting for
percent body fat (Fig. 3a). The relative decrease in plasma
adiponectin also correlated significantly with Δ-GS FV
activity before (r=0.32; p=0.026) but not significantly after
correction for percent body fat (Table 3).
The first 20 of 51 subjects enrolled in the present study
consisted of ten obese non-diabetic and ten obese type 2
diabetic male subjects. In these subjects we have
previously reported α1- and α2-AMPK activity, phosphor-
ylation of AMPK on Thr172, and phosphorylation of ACC
Fig. 1 Plasma adiponectin lev-
els (a, b) and glycogen synthase
activity given as percent frac-
tional velocity (GS FV) (c, d) at
basal (white bars) and at the end
(black bars) of a 4-h 40 mU·
m−2·min−1 euglycaemic–hyper-
insulinaemic clamp in ten lean,
21 obese and 20 type 2 diabetic
subjects. The percentage de-
crease in plasma adiponectin
levels (b) and the incremental
increase in GS FV (Δ-GS FV)
over basal (d) in response to
insulin infusion are shown for
lean (white bars), obese (grey
bars) and type 2 diabetic sub-
jects (black bars). Data are
means±SEM. *p<0.01 vs lean
subjects; #p<0.05 vs obese sub-
jects; §p<0.001 vs basal
Table 3 Relationship between plasma adiponectin and glycogen synthase activity in skeletal muscle
Basal plasma adiponectin Relative decrease in plasma adiponectin
r p r p
GS FV basal −0.02 0.92 −0.07 0.62
GS FV clamp 0.36 0.010 0.17 0.23
Δ-GS FV 0.44 0.002 0.26 0.067
Correlation coefficients after adjusting for percent body fat in a population of ten lean, 21 obese and 20 type 2 diabetic subjects
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Fig. 2 The relationship of basal
plasma adiponectin with rates
(mg·m−2·min−1) of (a) total glu-
cose disposal (Rd), (b) glucose
oxidation, (c) non-oxidative
glucose metabolism (NOGM)
and (d) lipid oxidation, as well
as (e) respiratory quotient (RQ)
and (f) serum NEFA at the end
of a 4-h 40 mU·m−2·min−1
euglycaemic–hyperinsulinaemic
clamp in a cross-sectional pop-
ulation of ten lean (triangles),
21 obese (open circles) and 20
type 2 diabetic subjects (closed
circles). Correlation coefficients
were adjusted for percent body
fat and are given for the total
population (r) and male subjects
alone (r′) (n=38)
Fig. 3 The relationship of basal
plasma adiponectin with (a) the
incremental increase of glyco-
gen synthase fractional velocity
over basal in response to insulin
infusion (Δ-GS FV) in a cross-
sectional population of ten lean
(triangles), 21 obese (open cir-
cles) and 20 type 2 diabetic
subjects (closedcircles), and
(b) with basal α2-AMPK activ-
ity in a subset of ten obese
(squares) non-diabetic subjects.
Correlation coefficients were
adjusted for percent body fat
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on Ser221 [26]. In this subpopulation of male subjects,
basal plasma adiponectin also correlated significantly with
Δ-GS FV activity (r=0.53; p=0.02 adjusted for percent
body fat) and tended to correlate with insulin-stimulated
values of GS FV activity (r=0.44; p=0.060 adjusted for
percent body fat). Basal plasma adiponectin showed no
relationship with either α1- or α2-AMPK activity, phos-
phorylation of α-AMPK on Thr172 or phosphorylation of
ACC on Ser221 in the total subpopulation. However, in the
subgroup of obese non-diabetic subjects, in which the
correlation between plasma adiponectin and Δ-GS FV
activity was conserved (r=0.69; p=0.04 adjusted for
percent body fat), we found a significant positive correla-
tion between plasma adiponectin and α2-AMPK activity
(r=0.87; p=0.002 adjusted for percent body fat) (Fig. 3b).
Discussion
The most important finding of the present study was the
relationship between plasma adiponectin and insulin
activation of GS in skeletal muscle. This provides a
possible explanation at the molecular level for the associ-
ation between plasma adiponectin and insulin-stimulated
NOGM, which was recently reported in offspring of
patients with type 2 diabetes [6], and now confirmed by us
in a cross-sectional population of middle-aged subjects.
Consistent with earlier reports [2–6, 8], we found a positive
association between plasma adiponectin and insulin-
stimulated Rd. Moreover, we report that plasma adiponectin
correlates positively with glucose oxidation and negatively
with lipid oxidation during insulin stimulation. This is
supported by the finding of a close positive association
between plasma adiponectin and insulin-stimulated RQ,
which reflects the capacity to switch from lipid to glucose
oxidation, also termed metabolic flexibility. These ob-
servations extend those previously reported in young
individuals with or without a family history of type 2
diabetes [4, 6]. Taken together our results indicate that the
insulin-sensitising effect of plasma adiponectin involves an
improved capacity to switch from lipid to glucose oxida-
tion and to store glucose as glycogen in response to insulin,
and that low plasma adiponectin in type 2 diabetes may
contribute to insulin resistance by interfering with insulin
action on GS in skeletal muscle.
The demonstration of a relationship between basal
plasma adiponectin and the capacity of insulin to stimulate
GS in skeletal muscle is a novel finding of the present
study. This suggests that low adiponectin levels may
contribute to impaired insulin activation of muscle GS,
which represents a consistent molecular abnormality in
skeletal muscle insulin resistance in individuals with
obesity, type 2 diabetes or a family history of diabetes
[29, 30], as well as human cultured myotubes obtained
from patients with type 2 diabetes [35]. The mechanism by
which plasma adiponectin interferes with insulin activation
of GS could involve modulation of proximal insulin
signalling components or of GS itself. Thus, in rodents the
administration of adiponectin enhances insulin-stimulated
tyrosine phosphorylation of the IR and IRS-1 in muscle
[14], and in humans plasma adiponectin was associated
with insulin-stimulated tyrosine phosphorylation of IR [5].
On the other hand, we and others have found normal distal
insulin signalling through Akt and GS kinase-3 despite
impaired insulin activation of GS in skeletal muscle of
patients with type 2 diabetes and myotubes established
from such subjects [30, 36–38]. Thus, it is possible that the
negative effect of low adiponectin is mediated directly by,
for example, lipid- and stress-activated kinases on GS, or
through as yet unknown signalling intermediates by
interfering with insulin-mediated dephosphorylation of GS.
Circulating adiponectin is predominantly present as
trimers, hexamers and high molecular weight (HMW)
forms [1]. Currently available clinical data support the
hypothesis that HMW adiponectin is the most physiologi-
cally relevant form [39, 40]. Only HMW adiponectin
shows the same strong associations with parameters of
insulin sensitivity as total adiponectin [39]. This is thought
to indicate that most of the reported relationships are
explained largely by HMWadiponectin. It is likely that this
includes the observed relationship between total adipo-
nectin and insulin-stimulated NOGM and GS in the present
study. However, further studies are warranted to explore
the direct molecular mechanisms by which these forms of
circulating adiponectin sensitise muscle to insulin action.
Females have higher circulating levels of total adiponectin,
and in particular the proportion of HMW and hexameric
adiponectin, than do males [1, 40, 41]. A selective
inhibition of the secretion of HMW adiponectin by
testosterone may contribute to these differences [42]. The
finding that the associations between plasma adiponectin
and measures of glucose and lipid metabolism as well as
insulin activation of GS remained intact in male subjects,
excludes the possibility that these relationships were due to
the larger variation in adiponectin induced by this sexual
dimorphism.
Using systemic indirect calorimetry, we found a reduced
insulin-stimulated RQ in type 2 diabetes and to a lesser
extent in obesity, and showed that the magnitude of this
response correlated positively with plasma adiponectin.
These results suggest a role for plasma adiponectin in
metabolic flexibility. Our data reflect whole-body substrate
oxidation, which makes it impossible to estimate the
relative contribution of insulin-sensitive tissues such as
liver, fat and muscle to this relationship. The finding of a
strong inverse association between plasma adiponectin and
the ability of insulin to suppress serum NEFA levels may
indicate a role for adiponectin in sensitising adipocytes to
the antilipolytic effect of insulin, and this could at least in
part explain the observed association between adiponectin
and insulin-mediated suppression of whole-body lipid
oxidation. On the other hand, measurement of RQ across
the tissue bed of the leg has shown that metabolic
inflexibility represents a characteristic feature of skeletal
muscle insulin resistance in type 2 diabetes and obesity
[43]. Therefore, it cannot be excluded that the observed
relationship between plasma adiponectin and insulin-
stimulated RQ also applies to skeletal muscle.
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There is experimental evidence that globular adiponectin
stimulates lipid oxidation in human myotubes [12] and
rodent skeletal muscle [13–15], and that this is mediated by
activation of AMPK [1, 12, 19], which has been shown to
induce mitochondrial biogenesis [20, 21]. Our finding of an
association between plasma adiponectin and muscle α2-
AMPK activity in a small group of non-diabetic obese
subjects, and a preliminary report of similar findings in
patients with type 2 diabetes [44], provide correlative
support for these mechanisms. However, in the present
study this relationship was absent in the total subpopulation
of healthy and type 2 diabetic obese male subjects. In
addition, reduced basal lipid oxidation in muscle, meta-
bolic inflexibility and lower plasma adiponectin levels in
type 2 diabetes and obesity are not reflected in lower
AMPK activity or altered protein expression of AMPK
isoforms in vivo compared with healthy lean subjects
[26–28]. Moreover, exercise-induced improvement of
insulin sensitivity, which is associated with increased
AMPK activity in both healthy and type 2 diabetic subjects
[28, 45], is not paralleled by increased plasma adiponectin
[46, 47]. Thus, there is no simple relationship between
plasma adiponectin, AMPK activity and insulin sensitivity
in skeletal muscle, and further studies are needed to
establish the role of adiponectin in metabolic flexibility and
mitochondrial function, and to what extent AMPK is
involved. This also suggests that adiponectin by its binding
to AdipoR1 or AdipoR2 may regulate other pathways in
order to mediate its insulin-sensitising effect in skeletal
muscle.
Another interesting finding of our study was that the
relative decrease in plasma adiponectin in response to
physiological hyperinsulinaemia for 4 h was blunted in
patients with type 2 diabetes. Other groups have speculated
that the suppression of plasma adiponectin in response to
physiological hyperinsulinaemia for 3–5 h might reflect the
relationship between hypoadiponectinaemia and chronic
hyperinsulinaemia [3, 48]. For several reasons this
explanation appears unlikely. Thus, in addition to the
blunted response in type 2 diabetic subjects, we found that
the insulin-mediated suppression of plasma adiponectin
was in fact associated with improved insulin action on Rd,
glucose oxidation, RQ and lipid oxidation. Also, the
decrease in plasma adiponectin during physiological
hyperinsulinaemia actually parallels the finding of sus-
tained activation of glucose metabolism and insulin
signalling molecules in response to insulin infusion for
3–4 h in humans [30, 36, 49], and insulin infusion for even
longer periods (8 h) improves mitochondrial ATP produc-
tion [50]. As with the ability of insulin to decrease plasma
adiponectin, these actions of insulin are impaired in
patients with type 2 diabetes, and are thought to contribute
to insulin resistance [30, 50]. Therefore, our data suggest
that insulin-mediated suppression of adiponectin may have
a physiological role, which may be beneficial rather than
simply reflecting the effect of chronic hyperinsulinaemia.
Our data, however, cannot demonstrate a cause and effect
relationship, and further studies are warranted to determine
the physiological relevance of this response.
In summary, we demonstrated a relationship between
plasma adiponectin and insulin action on glucose metab-
olism (oxidation and storage) and lipid oxidation. This was
reflected in a relationship between plasma adiponectin and
the ability of insulin to switch from mainly lipid to glucose
oxidation. These findings, although only correlative in
nature, indicate that low adiponectin levels may play a role
in the metabolic inflexibility associated with insulin
resistance in type 2 diabetes and obesity. Most importantly,
we hypothesised and demonstrated an association between
plasma adiponectin and insulin activation of GS in skeletal
muscle. This finding, for the first time, provides a potential
explanation at the molecular level for the insulin-sensitis-
ing effect of plasma adiponectin, and suggests that
therapeutic strategies that raise plasma adiponectin levels
would alleviate one of the most consistent defects in
skeletal muscle insulin resistance of patient with type 2
diabetes, namely impaired insulin activation of GS.
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